

## Chapter 7. Obstetrics, gynaecology, and urinary tract disorders







**Contents:**

[7.2 Treatment of vaginal and vulval conditions](#)

[7.3 Contraceptives](#)

[7.4 Drugs for genito-urinary disorders](#)

**Key**

	<p><b>Red drug</b> see <a href="#">GMMMG RAG list</a>  <i>Click on the symbols to access this list</i></p>
	<p><b>Amber drug</b> see <a href="#">GMMMG RAG list</a>  <i>Click on the symbols to access this list</i></p>
	<p><b>Green drug</b> see <a href="#">GMMMG RAG list</a>  <i>Click on the symbols to access this list</i></p>
	<p><b>If a medicine is unlicensed this should be highlighted in the template as follows</b>  <b>Drug name U</b></p>
	<p><b>Not Recommended</b></p>
	<p><b>Over the Counter</b>          In line with NHS England guidance, GM do not routinely support prescribing for conditions which are self-limiting or amenable to self-care. For further details see <a href="#">GM commissioning statement</a>.</p>
<p><b>Order of Drug Choice</b></p>	<p>Where there is no preferred 1<sup>st</sup> line agent provided, the drug choice appears in alphabetical order.</p>

<b>BNF chapter</b>	<b>7 Obstetrics, gynaecology, and urinary tract disorders</b> For hormonal therapy of gynaecological disorders see section 6.4.1 (including HRT), section 6.5.1 and 6.7.2.	
<b>Section</b>	<b>7.1 Drugs used in obstetrics</b>	
	<a href="#">NICE NG126: Ectopic pregnancy and miscarriage: diagnosis and initial management</a>	
<b>Section</b>	<b>7.2 Treatment of vaginal and vulval conditions</b>	
<b>Subsection</b>	<b>7.2.1 Preparations for vaginal and vulval changes</b>	
<b>Oestrogens, topical</b>		
<b>First choice</b>	<b>Estriol</b> 0.01% intravaginal cream (Gynest®)	
<b>Alternatives</b>	<b>Estriol</b> 500 microgram pessaries (Ortho-Gynest®)	
	<b>Estradiol</b> 10 microgram vaginal tablets (Vagifem®)	
<b>Subsection</b>	<b>7.2.2 Vaginal and vulval infections</b>	
<b>Preparations for vaginal and vulval candidiasis</b>		
<b>First choice</b>	<b>Fluconazole</b> (see section 5.2) Oral 150mg capsule	
	<b>Clotrimazole</b> 500mg pessary	
<b>Alternatives</b>	<b>Clotrimazole</b> Thrush cream (topical) 2%, Intravaginal cream 10% VC®	<a href="#">MHRA DSU (June 2016): Topical miconazole, including oral gel: reminder of potential for serious interactions with warfarin</a>
	<b>Miconazole Nitrate</b> 2% cream (Gyno-Daktarin®)	
<b>Preparations for other vaginal infections</b>		
<b>First choice</b>	<b>Metronidazole</b> Oral 400mg tablet	A dose of 400 mg twice a day for 5 to 7 days is recommended High-dose regimens (single oral dose of 2 g) are not recommended during pregnancy
<b>Alternatives</b>	<b>Metronidazole</b> vaginal gel 0.75%	
	<b>Clindamycin</b> vaginal cream 2%	

<b>Section</b>	<b>7.3 Contraceptives</b>	
	<a href="#">Faculty of Sexual &amp; Reproductive Healthcare Guidance</a> <a href="#">NICE PH51: Contraceptive services with a focus of young people up to the age of 25 years</a> <a href="#">NICE LGB17: Contraceptive Services</a> <a href="#">NICE PH3: Prevention of sexually transmitted infections and under 18 conceptions</a> <a href="#">NICE NG73: Endometriosis: diagnosis and management</a>	
<b>Subsection</b>	<b>7.3.1 Combined hormonal contraceptives (COCs)</b>	
	<p>When offering combined oral contraceptives first-line options are monophasic preparations containing 30micrograms of oestrogen, and either norethisterone or levonorgestrel. However all combined oral contraceptives can be considered based on patient acceptance.</p> <p><b>Other versions of combined oral contraceptives are available and are appropriate to be prescribed.</b></p> <p><b>The brand with the lowest acquisition cost and greatest ease of acquisition should be prescribed according to local choice.</b></p>	
	<b>Oral low strength (ethinylestradiol 20mcg)</b>	
	Loestrin 20®, Gedarel®20/150mcg, Milinette® 20/75mcg	
	<b>Oral standard strength (ethinylestradiol 30mcg)</b>	
	Levest®, Rigevidon®, Ovranelle®, Microgynon 30®, Loestrin 30®	
	<b>Oral standard strength (ethinylestradiol 35mcg)</b>	
	Ovysmen®, Brevinor®	
	<b>Monophasic (every day) standard strength</b>	
	Microgynon ED®	
	<b>Tri-phasic</b>	
	Logynon®	
	<b>Transdermal (standard strength)</b>	
	Evra® patches	Evra® is not recommended for routine use, but only for younger, or less compliant women, or those with GI disturbance whilst taking oral contraceptives.

<b>Subsection</b>	<b>7.3.2 Progestogen-only contraceptives</b>	
<b>Subsection</b>	<b>7.3.2.1 Oral progestogen-only contraceptives</b>	
<b>First choice</b>	<b>Norethisterone 350 micrograms</b> (Noriday®)	
<b>Alternatives</b>	<b>Levonorgestrel 30 micrograms</b> (Norgeston®)	
	<b>Desogestrel 75 micrograms</b> (Cerelle®, Aizea®)	Cerelle®/Aizea® should not routinely be used as an alternative to COCs but should be reserved for women who have problems adhering to the 3 hour window for other oral progestogen only contraceptives.
<b>Subsection</b>	<b>7.3.2.2 Parenteral progestogen-only contraceptives</b>	
	<a href="#">NICE CG30: Long-acting reversible contraception</a>	
<b>Injectable preparations</b>	<b>Medroxyprogesterone acetate</b> 150mg prefilled syringe (Depo-Provera®)  <b>Medroxyprogesterone acetate</b> 104mg prefilled injector device (Sayana Press®)	
<b>Implants</b>	<b>Etonogestrel</b> 68mg implant (Nexplanon® ▼)	<a href="#">MHRA DSU (June 2016): Nexplanon (etonogestrel) contraceptive implants: reports of device in vasculature and lung</a>  An implant should only be inserted subdermally and by a healthcare professional who has been <a href="#">appropriately trained and accredited</a>
<b>Subsection</b>	<b>7.3.2.3 Intra-uterine progestogen-only device</b>	
	<b>To be implanted by specially trained individuals only.</b> <a href="#">NICE NG88: Heavy menstrual bleeding: assessment and management</a> <a href="#">MHRA DSU: Intrauterine contraception: uterine perforation – updated information on risk factors</a> <a href="#">MHRA DSU: Levonorgestrel-releasing intrauterine systems: prescribe by brand name</a>	
<b>First choice</b>	<b>Levonorgestrel</b> 19.5 mg intra-uterine system (Kyleena®)	First choice for women requiring contraception. <a href="#">See GMMMG levonorgestrel-containing IUS comparison table</a>

<b>Alternatives</b>	<p><b>Levonorgestrel</b></p> <p>20micrograms/24 hours intra-uterine system (Levosert®)</p> <p>20micrograms/24 hours intra-uterine system (Mirena®)</p>	<p><a href="#">See GMMMG levonorgestrel-containing IUS comparison table</a></p> <p>Indicated for contraception and heavy menstrual bleeding.</p> <p>Indicated for contraception, idiopathic menorrhagia, and endometrial protection during oestrogen HRT.</p>
<b>Subsection</b>	<b>7.3.3 Spermicidal contraceptives</b>	
	<b>Nonoxinol '9'</b> 2% gel (Gygel®)	
<b>Subsection</b>	<b>7.3.4 Contraceptive devices</b>	
<b>Intra-uterine devices</b>		
<b>First choice</b>	<b>T-Safe® 380A Quickload</b>	
<b>Alternatives</b>	<b>Nova-T® 380, Flexi-T® 300</b>	

<b>Subsection</b>	<b>7.3.5 Emergency contraception</b>	
<p><a href="#">Faculty of Sexual &amp; Reproductive Healthcare guidelines</a> recommend that all eligible women should be offered the Cu-IUD as it is considered the most effective method of emergency contraception due to the low documented failure rate.</p>		
<b>Hormonal methods</b>		
<b>First choice</b>	<b>Ulipristal acetate</b> (EllaOne®)	<a href="#">FSRH guideline: emergency contraception</a>
<b>Alternatives</b>	<b>Levonorgestrel</b> (Levonelle® 1500)	

<b>BNF chapter</b>	<b>7 Obstetrics, gynaecology, and urinary tract disorders</b>	
<b>Section</b>	<b>7.4 Drugs for genito-urinary disorders</b> For drugs used in the treatment of urinary tract infections see section 5.1.13 For male sex hormones and antagonists see section 6.4.2 For gonadorelin analogues for prostate cancer see section 8.3.4.2	
<b>Subsection</b>	<b>7.4.1 Drugs for urinary retention</b>	
<b>Alpha blockers</b>		
<b>First choice</b>	<b>Tamsulosin</b> 400 microgram m/r capsules	<a href="#">NICE CG97: Lower urinary tract symptoms in men</a>
<b>Alternatives</b>	<b>Alfuzosin XL</b> 10mg m/r tablets <b>Doxazosin</b> 1mg, 2mg and 4mg tablets and 4mg MR tablets	
<b>Do Not Prescribe</b>	<b>Dutasteride/tamsulosin</b> 0.5mg/0.4mg hard capsules (Combodart®)	<a href="#">Criterion 3 (see RAG list)</a>
<b>Parasympathomimetics</b>		
Not recommended		
<b>Subsection</b>	<b>7.4.2 Drugs for urinary frequency, enuresis, and incontinence</b>	
<b>First choice drug to be continued for a minimum of four weeks</b> <a href="#">NICE NG123: Urinary incontinence and pelvic organ prolapse in women: management</a> <a href="#">NICE CG97: Lower urinary tract symptoms in men</a> <a href="#">GMMMG Treatment of overactive bladder in women</a>		
<b>First choice</b>	<b>Oxybutynin IR</b> 5mg tablets <b>Tolterodine IR</b> 2mg tablets	Oxybutynin not to be prescribed in frail elderly.
<b>Second choice</b>	<b>Darifenacin MR</b> 7.5mg tablets <b>Trospium MR</b> 60mg capsules	
Clinicians may want to use alternative agents within first and second choice before progressing to alternatives.		
<b>Alternatives</b>	<b>Oxybutynin transdermal patch</b> 36mg (releasing oxybutynin approx. 3.9 mg/24 hours)	<a href="#">NICE CG171: Urinary incontinence in women</a> : Offer a transdermal OAB drug to women unable to tolerate oral medication

	<p><b>Mirabegron<sup>▼</sup></b> 25mg or 50mg m/r tablets</p>	<p>Mirabegron is only recommended if antimuscarinic drugs are contraindicated or clinically ineffective or have unacceptable adverse effects.</p> <p><a href="#">MHRA Drug Update 2015: Mirabegron: risk of severe hypertension and associated cerebrovascular and cardiac events.</a></p> <p><a href="#">NICE TA290: Mirabegron for treating symptoms of overactive bladder</a></p>
<b>Additional notes</b>	<p><a href="#">NICE CG171</a> concluded that there is a lack of robust evidence to show a difference in clinical effectiveness between OAB drugs. The relative cost effectiveness was determined mostly by the difference in cost between them. NICE concluded that the lack of evidence showing long-term efficacy of OAB therapy should restrict the number of OAB drugs tried before seeking alternative recommended treatments.</p>	
<b>Subsection</b>	<p><b>7.4.3 Drugs used in urological pain</b></p>	
	<p><b>Alkalinisation of urine</b></p>	
	<p><b>Potassium citrate</b> (30%) mixture BP</p>	
	<p><b>Pentosan polysulfate sodium</b> 100 mg hard capsules (Elmiron<sup>®</sup>)</p>	<p style="text-align: center;"><b>R</b></p> <p><a href="#">NICE TA610: Pentosan polysulfate sodium for treating bladder pain syndrome</a></p>
<b>Do Not Prescribe</b>	<p><b>Mild cystitis (2-3 days)</b> Potassium citrate mixture or sachets, cranberry products</p> <p>See <a href="#">commissioning statement</a> for exceptions</p>	<p>In line with NHS England guidance, GM do not routinely support prescribing for conditions which are self-limiting or amenable to self-care. For further details see <a href="#">GM commissioning statement</a>.</p>
<b>Subsection</b>	<p><b>7.4.4 Bladder instillations and urological surgery</b></p>	
	<p><b>Glycine</b> irrigation solution <b>Sodium chloride 0.9%</b> <b>Sodium hyaluronate</b> (medical device)</p>	<p style="text-align: center;"><b>R</b></p>
	<p><b>Catheter patency solutions</b></p>	
	<p><b>Sodium chloride 0.9%</b> <b>Solution G</b> <b>Solution R</b></p>	



<b>Subsection</b>	<b>7.4.5 Drugs for erectile dysfunction</b>	
See guidance from:		
<ul style="list-style-type: none"> <li>British Society for Sexual Medicine: <a href="#">Guidelines on the Management of Erectile Dysfunction in Men—2017</a></li> <li>NICE Clinical Knowledge Summaries: <a href="#">Management of erectile dysfunction</a></li> </ul>		
<b>Phosphodiesterase type-5 inhibitors</b>		
<b>First choice</b>	<b>Sildenafil</b> 25mg, 50mg and 100mg tablets	<b>G<sub>n</sub></b>  Generic sildenafil is no longer subject to SLS restrictions and is therefore available for prescribers to prescribe to treat erectile dysfunction (ED).
<b>Alternative</b>	<b>Tadalafil</b> 10mg and 20mg tablets	<b>G<sub>n</sub></b>  Subject to SLS restrictions (see below)
<b>Do Not Prescribe</b>	<b>Tadalafil given once daily</b> Tablets	<u>Criterion 2 (see RAG list)</u> <u>See NHSE guidance on items not to be routinely prescribed in primary care</u>
	<b>Yohimbine</b> Supplement	<u>Criterion 1 (see RAG list)</u>
<b>Topical and injectable preparations</b>		
N.B. oral PDE-5 preparations would normally be first line therapy		
<b>Alternative</b>	<b>Alprostadil</b> 3mg/g cream (Vitaros®)	<b>G<sub>n</sub></b>  For use as a second line treatment option, as an alternative to intracavernous or intraurethral alprostadil injection.
	<b>Alprostadil</b> Intracavernosal injection: 5 microgram, 10 microgram, 20 microgram and 40 microgram (Caverject®, Viridal® Duo)	
<b>Alternative</b>	<b>Aviptadil and phentolamine</b> Solution for intracavernosal injection 25microgram/2mg (Invicorp®)	For those patients who have failed on PDE5 inhibitors and find alprostadil injections painful

**Additional notes:**

**Prescribing for erectile dysfunction on the NHS**

**BNF/ Drug Tariff approved uses**

Except for generic sildenafil, the above drugs are not available on NHS prescription except to treat erectile dysfunction in men who:

- have diabetes, multiple sclerosis, Parkinson’s disease, poliomyelitis, prostate cancer, severe pelvic injury, single gene neurological disease, spina bifida, or spinal cord injury;
- are receiving dialysis for renal failure;
- have had radical pelvic surgery, prostatectomy (including transurethral resection of the prostate), or kidney transplant;
- are suffering severe distress as a result of impotence (prescribed in specialist centres only, see notes below).

The prescription must be endorsed ‘SLS’.

**Severe distress caused by impotence**

The Department of Health (England) has recommended that treatment should also be available from specialist services (commissioned by Health Authorities and Primary Care Groups, and operating under local agreement) when the condition is causing severe distress; specialist centres should use form FP10(HP) and endorse it ‘SLS’ if the treatment is to be dispensed in the community. The following criteria should be considered when assessing distress:

- significant disruption to normal social and occupational activities;
- a marked effect on mood, behaviour, social and environmental awareness;
- a marked effect on interpersonal relationships.

Patients should be referred as per local commissioning arrangements.

<b>Subsection</b>	<b>7.4.6 Drugs for premature ejaculation</b>	
Do Not Prescribe	<b>Dapoxetine</b> Film-coated tablets	<u>Criterion 1 (see RAG list)</u>
Do Not Prescribe	<b>Licensed and off-label topical anaesthetics</b> For management of premature ejaculation	<u>Criterion 1 (see RAG list)</u>